ArticleLeukemia2017
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).Blood advances · 2021Trial
- A precision medicine classification for treatment of acute myeloid leukemia in older patients.Journal of hematology & oncology · 2021Trial
- Article
- A gene signature derived from leukemia associated macrophages provides a compelling risk stratification for human AML patients.Biomarker research · 2026Article
- A case report of BCR-ABL(+) acute myeloid leukemia and literature review.Frontiers in oncology · 2026Article
- Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma.bioRxiv : the preprint server for biology · 2025Article
- Article
- Prognostic and Therapeutic Implications ofbioRxiv : the preprint server for biology · 2025Article
- Budget impact analysis of revumenib for the treatment of relapsed or refractory acute leukemias with aJournal of managed care & specialty pharmacy · 2025Article
- Current developments in T-cell receptor therapy for acute myeloid leukemia.Blood advances · 2025Review
- Article
- The road not taken: Exploring non-transplant options in De Novo philadelphia positive acute myeloid leukemia.Leukemia research reports · 2025Article
- White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years.American journal of hematology · 2024Article
- Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.Leukemia · 2024Article
- Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.Blood cancer journal · 2024Article
- Appraisal of current technologies for the study of genetic alterations in hematologic malignancies with a focus on chromosome analysis and structural variants.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2024Article
- Article
- Case report: One case of acute myeloid leukemia M3 with atypical morphology.Frontiers in oncology · 2024Article
- Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) withInternational journal of molecular sciences · 2023Article
- Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.Blood advances · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML patients, and are used to denote specific disease entities in the World Health Organization classification of myeloid neoplasms and acute leukemia. However, large studies that integrate cytogenetic and comprehensive mutational information are scarce. We created a comprehensive oncoprint of mutations associated with recurrent cytogenetic findings by combining the information on mutational patterns of 80 cancer- and leukemia-associated genes with cytogenetic findings in 1603 adult patients with de novo AML. We show unique differences in the mutational profiles among major cytogenetic subsets, identify novel associations between recurrent cytogenetic abnormalities and both specific gene mutations and gene functional groups, and reveal differences in cytogenetic and mutational features between patients younger than 60 years and those aged 60 years or older. The identified associations between cytogenetic and molecular genetic data may help guide mutation testing in AML, and result in more focused application of targeted therapy in patients with de novo AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.